- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6 result(s) found for: Avapritinib.
Displaying page 1 of 1.
EudraCT Number: 2020-005234-15 | Sponsor Protocol Number: BLU-285-3101 | Start Date*: Information not available in EudraCT |
Sponsor Name:Blueprint Medicines Corporation | ||
Full Title: A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling | ||
Medical condition: Solid Tumors Dependent on KIT or PDGFRA Signaling | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) AT (Ongoing) IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000588-99 | Sponsor Protocol Number: BLU-285-2203 | Start Date*: 2019-03-15 | ||||||||||||||||
Sponsor Name:Blueprint Medicines Corporation | ||||||||||||||||||
Full Title: A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indole... | ||||||||||||||||||
Medical condition: Indolent Systemic Mastocytosis (ISM) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Ongoing) DE (Ongoing) ES (Ongoing) NL (Ongoing) DK (Ongoing) IT (Ongoing) SE (Ongoing) FR (Ongoing) NO (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005751-21 | Sponsor Protocol Number: BLU-285-1408 | Start Date*: 2021-04-16 | |||||||||||||||||||||
Sponsor Name:Blueprint Medicines | |||||||||||||||||||||||
Full Title: Open-Label Extension Study to Evaluate the Safety of Long-Term Treatment with Avapritinib for Patients Previously Involved in an Avapritinib Study | |||||||||||||||||||||||
Medical condition: Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003497-14 | Sponsor Protocol Number: BLU-285-1303 | Start Date*: 2018-04-23 | ||||||||||||||||
Sponsor Name:Blueprint Medicines Corporation | ||||||||||||||||||
Full Title: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) | ||||||||||||||||||
Medical condition: Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) SE (Completed) HU (Completed) DE (Completed) NL (Completed) AT (Completed) ES (Completed) BE (Completed) CZ (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004836-13 | Sponsor Protocol Number: BLU-285-2202 | Start Date*: 2018-12-29 | |||||||||||
Sponsor Name:Blueprint Medicines Corporation | |||||||||||||
Full Title: An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Ma... | |||||||||||||
Medical condition: Advanced Systemic Mastocytosis (AdvSM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) GB (GB - no longer in EU/EEA) DE (Ongoing) ES (Ongoing) PL (Completed) AT (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001535-87 | Sponsor Protocol Number: BLU-263-2101 | Start Date*: 2023-02-03 | ||||||||||||||||
Sponsor Name:Blueprint Medicines Corporation | ||||||||||||||||||
Full Title: A Phase 1/2, open-label, 2-arm study evaluating BLU-263 as monotherapy and in combination with azacitidine, in patients with KIT altered hematologic malignancies | ||||||||||||||||||
Medical condition: Advanced Systemic Mastocytosis (AdvSM) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NO (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.